Evrópusambandið - spænska - EMA (European Medicines Agency)

boehringer ingelheim international gmbh - dabigatrán etexilato mesilate - arthroplasty, replacement; venous thromboembolism - agentes antitrombóticos - pradaxa 75 mgprimary la prevención de eventos tromboembólicos venosos en pacientes adultos que han sufrido electiva total de la cirugía de reemplazo de cadera o cirugía de reemplazo total de rodilla. pradaxa 110 mgprimary la prevención de eventos tromboembólicos venosos en pacientes adultos que han sufrido electiva total de la cirugía de reemplazo de cadera o cirugía de reemplazo total de rodilla. prevención del ictus y la embolia sistémica en pacientes adultos con fibrilación auricular no valvular no valvular (fanv), con uno o más factores de riesgo, tales como antecedente de accidente cerebrovascular o ataque isquémico transitorio (ait); edad ≥ 75 años; insuficiencia cardíaca (clase nyha ≥ ii); diabetes mellitus; hipertensión. tratamiento de la trombosis venosa profunda (tvp) y embolia pulmonar (pe), y la prevención de la recurrencia de la tvp y de la ep en los adultos. pradaxa 150 mgprevention de ictus y embolia sistémica en pacientes adultos con fibrilación auricular no valvular no valvular (fanv), con uno o más factores de riesgo, tales como antecedente de accidente cerebrovascular o ataque isquémico transitorio (ait); edad ≥ 75 años; insuficiencia cardíaca (clase nyha ≥ ii); diabetes mellitus; hipertensión. tratamiento de la trombosis venosa profunda (tvp) y embolia pulmonar (pe), y la prevención de la recurrencia de la tvp y de la ep en los adultos.

Evrópusambandið - franska - EMA (European Medicines Agency)

boehringer ingelheim international gmbh - le dabigatran etexilate mésilate - arthroplasty, replacement; venous thromboembolism - agents antithrombotiques - pradaxa 75 mgprimary la prévention des événements thromboemboliques veineux chez les patients adultes qui ont subi une arthroplastie totale non urgente de la hanche ou chirurgie de remplacement total du genou chirurgie. pradaxa 110 mgprimary la prévention des événements thromboemboliques veineux chez les patients adultes qui ont subi une arthroplastie totale non urgente de la hanche ou chirurgie de remplacement total du genou chirurgie. prévention des avc et des embolies systémiques chez des patients adultes atteints de fa non valvulaire (nvaf), avec un ou plusieurs facteurs de risque, comme les antécédents d'avc ou d'accident ischémique transitoire (tia); âge ≥ 75 ans; l'insuffisance cardiaque (classe nyha ≥ ii); diabète; hypertension. le traitement de la thrombose veineuse profonde (tvp) et l'embolie pulmonaire (ep) et prévention des récidives de tvp et l'ep chez les adultes. pradaxa 150 mgprevention de l'avc et de l'embolie systémique chez les adultes atteints de fa non valvulaire (nvaf), avec un ou plusieurs facteurs de risque, comme les antécédents d'avc ou d'accident ischémique transitoire (tia); âge ≥ 75 ans; l'insuffisance cardiaque (classe nyha ≥ ii); diabète; hypertension. le traitement de la thrombose veineuse profonde (tvp) et l'embolie pulmonaire (ep) et prévention des récidives de tvp et l'ep chez les adultes.

Evrópusambandið - enska - EMA (European Medicines Agency)

boehringer ingelheim international gmbh - dabigatran etexilate mesilate - arthroplasty, replacement; venous thromboembolism - antithrombotic agents - pradaxa 75 mgprimary prevention of venous thromboembolic events in adult patients who have undergone elective total hip replacement surgery or total knee replacement surgery.pradaxa 110 mgprimary prevention of venous thromboembolic events in adult patients who have undergone elective total hip replacement surgery or total knee replacement surgery.prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (nvaf), with one or more risk factors, such as prior stroke or transient ischemic attack (tia); age ≥ 75 years; heart failure (nyha class ≥ ii); diabetes mellitus; hypertension.treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults.pradaxa 150 mgprevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (nvaf), with one or more risk factors, such as prior stroke or transient ischemic attack (tia); age ≥ 75 years; heart failure (nyha class ≥ ii); diabetes mellitus; hypertension.treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults.

Serbía - serbneska - Агенција за лекове и медицинска средства Србије (Agencija za lekove i medicins)

boehringer ingelheim serbia d.o.o. beograd - dabigatraneteksilat - kapsula, tvrda - 110mg

Evrópusambandið - gríska - EMA (European Medicines Agency)

boehringer ingelheim international gmbh - dabigatran etexilate mesilate - arthroplasty, replacement; venous thromboembolism - Αντιθρομβωτικοί παράγοντες - Το pradaxa 75 mgprimary πρόληψη των φλεβικών θρομβοεμβολικών επεισοδίων σε ενήλικες ασθενείς οι οποίοι έχουν υποβληθεί σε εκλεκτική σύνολο χειρουργική επέμβαση αντικατάστασης ισχίου ή γόνατος χειρουργική επέμβαση. Το pradaxa 110 mgprimary πρόληψη των φλεβικών θρομβοεμβολικών επεισοδίων σε ενήλικες ασθενείς οι οποίοι έχουν υποβληθεί σε εκλεκτική σύνολο χειρουργική επέμβαση αντικατάστασης ισχίου ή γόνατος χειρουργική επέμβαση. Πρόληψη του εγκεφαλικού επεισοδίου και συστηματικής εμβολής σε ενήλικες ασθενείς με μη-βαλβιδική κολπική μαρμαρυγή (nvaf), με έναν ή περισσότερους παράγοντες κινδύνου, όπως πριν από εγκεφαλικό επεισόδιο ή παροδικό ισχαιμικό επεισόδιο (tia) ηλικία ≥ 75 ετών, καρδιακή ανεπάρκεια (nyha class ≥ ΙΙ), σακχαρώδης διαβήτης, υπέρταση. Θεραπεία της φλεβικής θρόμβωσης (ΕΒΦΘ) και της πνευμονικής εμβολής (πε), και πρόληψη υποτροπιάζουσας ΕΒΦΘ και πε σε ενήλικες. Το pradaxa 150 mgprevention του εγκεφαλικού επεισοδίου και συστηματικής εμβολής σε ενήλικες ασθενείς με μη-βαλβιδική κολπική μαρμαρυγή (nvaf), με έναν ή περισσότερους παράγοντες κινδύνου, όπως πριν από εγκεφαλικό επεισόδιο ή παροδικό ισχαιμικό επεισόδιο (tia) ηλικία ≥ 75 ετών, καρδιακή ανεπάρκεια (nyha class ≥ ΙΙ), σακχαρώδης διαβήτης, υπέρταση. Θεραπεία της φλεβικής θρόμβωσης (ΕΒΦΘ) και της πνευμονικής εμβολής (πε), και πρόληψη υποτροπιάζουσας ΕΒΦΘ και πε σε ενήλικες.

Serbía - serbneska - Агенција за лекове и медицинска средства Србије (Agencija za lekove i medicins)

boehringer ingelheim serbia d.o.o. beograd - dabigatraneteksilat - kapsula, tvrda - 150mg

Serbía - serbneska - Агенција за лекове и медицинска средства Србије (Agencija za lekove i medicins)

boehringer ingelheim serbia d.o.o. beograd - dabigatraneteksilat -

Evrópusambandið - ungverska - EMA (European Medicines Agency)

boehringer ingelheim international gmbh - dabigatran etexilát mesilate - arthroplasty, replacement; venous thromboembolism - antitrombotikus szerek - a pradaxa 75 mgprimary vénás thromboemboliás események felnőtt betegeknél, akik átestek elektív, teljes csípőprotézis műtét, vagy teljes térdprotézis műtét. a pradaxa 110 mgprimary vénás thromboemboliás események felnőtt betegeknél, akik átestek elektív, teljes csípőprotézis műtét, vagy teljes térdprotézis műtét. a stroke megelőzése, valamint a szisztémás embólia szenvedő felnőtteknél, akik nem valvular pitvarfibrilláció (nvaf), egy vagy több kockázati tényezők, mint a megelőző stroke vagy tranziens ischaemiás attack (tia); életkor ≥ 75 év; szívelégtelenség (nyha ≥ ii.); cukorbetegség, a magas vérnyomás. kezelés a mélyvénás trombózis (dvt), mind a pulmonalis embolia (pe), illetve megelőzése, a visszatérő mvt, illetve pe felnőttek. a pradaxa 150 mgprevention a stroke, valamint szisztémás embólia szenvedő felnőtteknél, akik nem valvular pitvarfibrilláció (nvaf), egy vagy több kockázati tényezők, mint a megelőző stroke vagy tranziens ischaemiás attack (tia); életkor ≥ 75 év; szívelégtelenség (nyha ≥ ii.); cukorbetegség, a magas vérnyomás. kezelés a mélyvénás trombózis (dvt), mind a pulmonalis embolia (pe), illetve megelőzése, a visszatérő mvt, illetve pe felnőttek.

Bandaríkin - enska - NLM (National Library of Medicine)

a-s medication solutions - dabigatran etexilate mesylate (unii: sc7nuw5iit) (dabigatran - unii:i0vm4m70gc) - pradaxa is indicated to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation. pradaxa is indicated for the treatment of deep venous thrombosis and pulmonary embolism in patients who have been treated with a parenteral anticoagulant for 5-10 days. pradaxa is indicated to reduce the risk of recurrence of deep venous thrombosis and pulmonary embolism in patients who have been previously treated. pradaxa is indicated for the prophylaxis of deep vein thrombosis and pulmonary embolism, in patients who have undergone hip replacement surgery. pradaxa is contraindicated in patients with: - active pathological bleeding [see warnings and precautions (5.2) and adverse reactions (6.1)] . - history of a serious hypersensitivity reaction to pradaxa (e.g., anaphylactic reaction or anaphylactic shock) [see adverse reactions (6.1)] . - mechanical prosthetic heart valve [see warnings and precautions (5.4)]. risk summary the limited available data on pradaxa use in pregnant wo

Bandaríkin - enska - NLM (National Library of Medicine)

a-s medication solutions - dabigatran etexilate mesylate (unii: sc7nuw5iit) (dabigatran - unii:i0vm4m70gc) - pradaxa capsules is indicated to reduce the risk of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation. pradaxa capsules is indicated for the treatment of deep venous thrombosis and pulmonary embolism in adult patients who have been treated with a parenteral anticoagulant for 5-10 days. pradaxa capsules is indicated to reduce the risk of recurrence of deep venous thrombosis and pulmonary embolism in adult patients who have been previously treated. pradaxa capsules is indicated for the prophylaxis of deep vein thrombosis and pulmonary embolism in adult patients who have undergone hip replacement surgery. pradaxa capsules is indicated for the treatment of venous thromboembolic events (vte) in pediatric patients 8 to less than 18 years of age who have been treated with a parenteral anticoagulant for at least 5 days [see dosage and administration (2.3)] . pradaxa capsules is indicated to reduce the risk of recurrence of vte in pediatric patients 8 to less than 18 years of age who have been previously treated [see dosage and administration (2.3)] . pradaxa is contraindicated in patients with: - active pathological bleeding [see warnings and precautions (5.2) and adverse reactions (6.1)] - history of a serious hypersensitivity reaction to dabigatran, dabigatran etexilate, or to one of the excipients of the product (e.g., anaphylactic reaction or anaphylactic shock) [see adverse reactions (6.1)] - mechanical prosthetic heart valve [see warnings and precautions (5.4)] risk summary the limited available data on pradaxa use in pregnant women are insufficient to determine drug-associated risks for adverse developmental outcomes. there are risks to the mother associated with untreated venous thromboembolism in pregnancy and a risk of hemorrhage in the mother and fetus associated with the use of anticoagulants (see clinical considerations) . in pregnant rats treated from implantation until weaning, dabigatran increased the number of dead offspring and caused excess vaginal/uterine bleeding close to parturition at an exposure 2.6 times the human exposure. at a similar exposure, dabigatran decreased the number of implantations when rats were treated prior to mating and up to implantation (gestation day 6). dabigatran administered to pregnant rats and rabbits during organogenesis up to exposures 8 and 13 times the human exposure, respectively, did not induce major malformations. however, the incidence of delayed or irregular ossification of fetal skull bones and vertebrae was increased in the rat (see data) . the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2%-4% and 15%-20%, respectively. clinical considerations disease-associated maternal and/or embryo/fetal risk pregnancy confers an increased risk for thromboembolism that is higher for women with underlying thromboembolic disease and certain high-risk pregnancy conditions. published data describe that women with a previous history of venous thrombosis are at high risk for recurrence during pregnancy. fetal/neonatal adverse reaction use of anticoagulants, including pradaxa, may increase the risk of bleeding in the fetus and neonate. monitor neonates for bleeding [see warnings and precautions (5.2)]. labor or delivery all patients receiving anticoagulants, including pregnant women, are at risk for bleeding. pradaxa use during labor or delivery in women who are receiving neuraxial anesthesia may result in epidural or spinal hematomas. consider discontinuation or use of shorter acting anticoagulant as delivery approaches [see warnings and precautions (5.2, 5.3)] . data animal data dabigatran has been shown to decrease the number of implantations when male and female rats were treated at a dosage of 70 mg/kg (about 2.6 to 3.0 times the human exposure at mrhd of 300 mg/day based on area under the curve [auc] comparisons) prior to mating and up to implantation (gestation day 6). treatment of pregnant rats after implantation with dabigatran at the same dose increased the number of dead offspring and caused excess vaginal/uterine bleeding close to parturition. dabigatran administered to pregnant rats and rabbits during organogenesis up to maternally toxic doses of 200 mg/kg (8 and 13 times the human exposure, respectively, at a mrhd of 300 mg/day based on auc comparisons) did not induce major malformations, but increased the incidence of delayed or irregular ossification of fetal skull bones and vertebrae in the rat. death of offspring and mother rats during labor in association with uterine bleeding occurred during treatment of pregnant rats from implantation (gestation day 7) to weaning (lactation day 21) with dabigatran at a dose of 70 mg/kg (about 2.6 times the human exposure at mrhd of 300 mg/day based on auc comparisons). risk summary there are no data on the presence of dabigatran in human milk, the effects on the breastfed child, or on milk production. dabigatran and/or its metabolites were present in rat milk. breastfeeding is not recommended during treatment with pradaxa. females of reproductive potential requiring anticoagulation should discuss pregnancy planning with their physician. the risk of clinically significant uterine bleeding, potentially requiring gynecological surgical interventions, identified with oral anticoagulants including pradaxa should be assessed in females of reproductive potential and those with abnormal uterine bleeding. the safety and effectiveness of pradaxa capsules for the treatment and the reduction in risk of recurrence of venous thromboembolism have been established in pediatric patients 8 to less than 18 years of age. use of pradaxa for this indication is supported by evidence from adequate and well-controlled studies in pediatric patients. these studies included an open-label, randomized, parallel-group study and an open-label, single-arm safety study [see adverse reactions (6.1) and clinical studies (14.4, 14.5)] . other age-appropriate pediatric dosage forms of dabigatran etexilate are available for pediatric patients less than 8 years of age for these indications. safety and effectiveness of pradaxa capsules have not been established in pediatric patients with non-valvular atrial fibrillation or those who have undergone hip replacement surgery. of the total number of patients in the re-ly study, 82% were 65 and over, while 40% were 75 and over. the risk of stroke and bleeding increases with age, but the risk-benefit profile is favorable in all age groups [see warnings and precautions (5), adverse reactions (6.1), and clinical studies (14.1)] . reduction of risk of stroke and systemic embolism in non-valvular atrial fibrillation in adult patients no dose adjustment of pradaxa is recommended in patients with mild or moderate renal impairment [see clinical pharmacology (12.3)] . reduce the dose of pradaxa in patients with severe renal impairment (crcl 15-30 ml/min) [see dosage and administration (2.2, 2.4) and clinical pharmacology (12.3)] . dosing recommendations for patients with crcl < 15 ml/min or on dialysis cannot be provided. adjust dose appropriately in patients with renal impairment receiving concomitant p-gp inhibitors [see warnings and precautions (5.5), drug interactions (7.1), and clinical pharmacology (12.3)]. treatment and reduction in the risk of recurrence of deep venous thrombosis and pulmonary embolism in adult patients patients with severe renal impairment (crcl ≤ 30 ml/min) were excluded from re-cover. dosing recommendations for patients with crcl ≤ 30 ml/min or on dialysis cannot be provided. avoid use of pradaxa with concomitant p-gp inhibitors in patients with crcl < 50 ml/min [see warnings and precautions (5.5), drug interactions (7.2), and clinical pharmacology (12.3)]. prophylaxis of deep vein thrombosis and pulmonary embolism in adult patients following hip replacement surgery patients with severe renal impairment (crcl < 30 ml/min) were excluded from re-novate and re-novate ii. dosing recommendations for patients with crcl < 30 ml/min or on dialysis cannot be provided. avoid use of pradaxa with concomitant p-gp inhibitors in patients with crcl < 50 ml/min [see warnings and precautions (5.5), drug interactions (7.3), and clinical pharmacology (12.2, 12.3)]. treatment and reduction in the risk of recurrence of vte in pediatric patients pradaxa has not been studied in pediatric patients with egfr < 50 ml/min/1.73 m2 . reduced renal function could increase exposure. dosing recommendations cannot be provided for treatment of these patients. avoid use of pradaxa capsules in these patients [see dosage and administration (2.4)].